Baxter International Inc.
BAX
株式のランク
#1643
Baxter International Inc., operating globally via its subsidiaries, is a... Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
株価
$25.29
最終同期: 2026-10-16
時価総額
$13.07B
変化（1日）
-1.79%
変化（1年）
9.51%
国
US
取引 Baxter International Inc. (BAX)
カテゴリー
Healthcare
Baxter International Inc.（BAX）の営業利益率
October 2026 時点の営業利益率 TTM: -2.39%
Baxter International Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は -2.39% です。2023 年末時点では 6.82% でした。
Baxter International Inc. の営業利益率の履歴（2000 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | -2.39% | -1,938.46% |
| 2024 | 0.13% | -98.09% |
| 2023 | 6.82% | -124.11% |
| 2022 | -28.29% | -354.64% |
| 2021 | 11.11% | -19.73% |
| 2020 | 13.84% | -11.28% |
| 2019 | 15.60% | 9.32% |
| 2018 | 14.27% | 17.26% |
| 2017 | 12.17% | 66.03% |
| 2016 | 7.33% | 62.89% |
| 2015 | 4.50% | -26.47% |
| 2014 | 6.12% | 16.13% |
| 2013 | 5.27% | -73.96% |
| 2012 | 20.24% | -4.53% |
| 2011 | 21.20% | 27.48% |
| 2010 | 16.63% | -27.38% |
| 2009 | 22.90% | 10.31% |
| 2008 | 20.76% | 7.84% |
| 2007 | 19.25% | 8.51% |
| 2006 | 17.74% | 6.61% |
| 2005 | 16.64% | 76.83% |
| 2004 | 9.41% | -33.40% |
| 2003 | 14.13% | -25.16% |
| 2002 | 18.88% | 13.53% |
| 2001 | 16.63% | 7.71% |
| 2000 | 15.44% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 31.28% | -113.09% |
US
|
|
| 12.36% | -105.17% |
FR
|
|
| 0.00% | - |
JP
|
|
| 9.83% | -104.11% |
US
|
|
| 0.00% | - |
CH
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。